166 related articles for article (PubMed ID: 38483213)
21. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
22. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
24. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study.
Sahebi F; Shen Y; Thomas SH; Rincon A; Murata-Collins J; Palmer J; Krishnan AY; Karanes C; Htut M; Somlo G; Forman SJ
Br J Haematol; 2013 Jan; 160(2):199-206. PubMed ID: 23151215
[TBL] [Abstract][Full Text] [Related]
25. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.
Tang W; Fan X; Wang L; Hu J
Medicine (Baltimore); 2015 Apr; 94(15):e706. PubMed ID: 25881847
[TBL] [Abstract][Full Text] [Related]
26. Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
Ueda T; Maeda T; Kusakabe S; Fujita J; Fukushima K; Yokota T; Shibayama H; Tomiyama Y; Kanakura Y
Int J Hematol; 2019 Feb; 109(2):197-205. PubMed ID: 30448938
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma.
Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Skarbnik AP; Richter J; Pecora A; Siegel DS
Bone Marrow Transplant; 2019 Nov; 54(11):1881-1891. PubMed ID: 31101891
[TBL] [Abstract][Full Text] [Related]
28. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
[TBL] [Abstract][Full Text] [Related]
30. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
[TBL] [Abstract][Full Text] [Related]
31. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
[TBL] [Abstract][Full Text] [Related]
32. [Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].
Inamoto Y; Kuwatsuka Y; Tsujimura A; Tokunaga M; Oba T; Miyamura K; Kodera Y
Rinsho Ketsueki; 2006 Jan; 47(1):9-15. PubMed ID: 16479977
[TBL] [Abstract][Full Text] [Related]
33. Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.
Wong JY; Forman S; Somlo G; Rosenthal J; Liu A; Schultheiss T; Radany E; Palmer J; Stein A
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):148-56. PubMed ID: 22592050
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
[TBL] [Abstract][Full Text] [Related]
35. Total Marrow Irradiation for Second Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia.
Dominietto A; Vagge S; di Grazia C; Bregante S; Raiola AM; Varaldo R; Gualandi F; Gusinu M; Barra S; Agostinelli S; Angelucci E; Hui S
Transplant Cell Ther; 2023 Aug; 29(8):506.e1-506.e6. PubMed ID: 37094701
[TBL] [Abstract][Full Text] [Related]
36. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Hawkins D; Barnett T; Bensinger W; Gooley T; Sanders J
Med Pediatr Oncol; 2000 May; 34(5):328-37. PubMed ID: 10797354
[TBL] [Abstract][Full Text] [Related]
37. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Giralt S; Thall PF; Khouri I; Wang X; Braunschweig I; Ippolitti C; Claxton D; Donato M; Bruton J; Cohen A; Davis M; Andersson BS; Anderlini P; Gajewski J; Kornblau S; Andreeff M; Przepiorka D; Ueno NT; Molldrem J; Champlin R
Blood; 2001 Feb; 97(3):631-7. PubMed ID: 11157478
[TBL] [Abstract][Full Text] [Related]
38. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
39. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.
Ladbury C; Somlo G; Dagis A; Yang D; Armenian S; Song JY; Sahebi F; Spielberger R; Popplewell L; Parker P; Forman S; Snyder D; Rincon A; Liu A; Frankel P; Wong J
Transplant Cell Ther; 2022 Jul; 28(7):367.e1-367.e9. PubMed ID: 35534000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
